Novo Nordisk (NVO) EBITDA (2014 - 2026)
Novo Nordisk (NVO) EBITDA from Dec 31, 2014 to Mar 31, 2026. The TTM Novo Nordisk (NVO) EBITDA is $29B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Novo Nordisk (NVO) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +22.29% |
| 3 Years TTM | +35.92% |
| 5 Years TTM | +25.26% |
| 10 Years TTM | +15.76% |
| All Time TTM | +15.10% |
Annual EBITDA change of Novo Nordisk (NVO)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $11B | -56.57% |
| 2025 | $25B | +19.96% |
| 2024 | $21B | +21.02% |
| 2023 | $17B | +53.57% |
| 2022 | $11B | +10.51% |
| 2021 | $10B | +2.76% |
| 2020 | $9.73B | +19.09% |
| 2019 | $8.17B | +3.11% |
| 2018 | $7.93B | -5.31% |
| 2017 | $8.37B | +15.84% |
| 2016 | $7.23B | +6.77% |
| 2015 | $6.77B | +10.79% |
| 2014 | $6.11B | N/A |
Comparison Novo Nordisk (NVO) five years EBITDA CAGR with competitors
Novo Nordisk (NVO) five years EBITDA CAGR is 25.26%.
| Ticker | Name | five years EBITDA CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 30.95% | +22.54% |
| AZN | Astrazeneca plc | 18.02% | -28.64% |
| GILD | Gilead Sciences Inc | 17.19% | -31.93% |
| BMY | Bristol-Myers Squibb Company | 13.61% | -46.13% |
| MRK | Merck & Co Inc | 10.17% | -59.76% |
| JNJ | Johnson & Johnson | 6.13% | -75.71% |
| ABBV | Abbvie Inc | 4.99% | -80.23% |
| AMGN | AMGEN Inc | 4.42% | -82.51% |
| GRFS | Grifols SA | 2.72% | -89.21% |
| GSK | GSK Plc | 1.17% | -95.38% |